Literature DB >> 4077073

Cardiac arrhythmias during cytotoxic chemotherapy: role of domperidone.

R J Osborne, M L Slevin, R W Hunter, J Hamer.   

Abstract

Four patients receiving platinum-containing chemotherapy were treated with domperidone (20 mg) by slow intravenous injection followed by a continuous infusion for 24 h at a dose of 10 mg 24 h-1 kg-1. Cardiac monitoring and plasma potassium and domperidone concentration measurements were performed. Severe cardiac arrhythmias occurred in two patients. A control group of 14 patients treated with similar chemotherapy, without domperidone, also underwent cardiac and plasma potassium monitoring. No significant arrhythmias were seen. The electrophysiologic effects of domperidone are discussed. It is concluded that treatment with intravenous domperidone is associated with the occurrence of cardiac arrhythmias.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4077073     DOI: 10.1177/096032718500400608

Source DB:  PubMed          Journal:  Hum Toxicol        ISSN: 0144-5952


  13 in total

1.  Increased risk of all-cause mortality associated with domperidone use in Parkinson's patients: a population-based cohort study in the UK.

Authors:  Marina Simeonova; Frank de Vries; Sander Pouwels; Johanna H M Driessen; Hubert G M Leufkens; Suzanne M Cadarette; Andrea M Burden
Journal:  Br J Clin Pharmacol       Date:  2018-08-09       Impact factor: 4.335

2.  Epirubicin cytotoxicity but not oxygen radical formation is enhanced by four different antiemetics.

Authors:  R Henriksson; K Grankvist
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

Review 3.  Domperidone-associated sudden cardiac death in the general population and implications for use in patients undergoing hemodialysis: a literature review.

Authors:  Joy Makari; Karen Cameron; Marisa Battistella
Journal:  Can J Hosp Pharm       Date:  2014-11

4.  A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response.

Authors:  J Carmichael; B M Cantwell; C M Edwards; B D Zussman; S Thompson; W G Rapeport; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  QT interval prolongation associated with the oral use of domperidone in an infant.

Authors:  C M G Rocha; M M Barbosa
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

6.  Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro.

Authors:  Bryan A Ward; Alan Morocho; Abdullah Kandil; Raymond E Galinsky; David A Flockhart; Zeruesenay Desta
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

7.  Population pharmacokinetics of domperidone in preterm neonates.

Authors:  E Dailly; M H Drouineau; V Gournay; J C Rozé; P Jolliet
Journal:  Eur J Clin Pharmacol       Date:  2008-08-07       Impact factor: 2.953

Review 8.  Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children.

Authors:  L Lee Dupuis; Paul C Nathan
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease.

Authors:  J Carmichael; P A Philip; C Forfar; A L Harris
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Effect of domperidone on the QTc interval in premature infants.

Authors:  A Günlemez; A Babaoğlu; A E Arisoy; G Türker; A S Gökalp
Journal:  J Perinatol       Date:  2009-07-23       Impact factor: 2.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.